9 completed, 6 active not recruiting, 4 terminated, 2 unknown. 9 Phase 2, 7 Phase 3, 3 Early Phase 1, 3 Phase 1, 1 Not applicable.
Follow Fallopian Tube Serous Adenocarcinoma: new trials by email Literature Review of Fallopian Tube Serous Adenocarcinoma trials Research Report on Fallopian Tube Serous Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Bevacizumab, Biopsy, Biospecimen Collection - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 60 | 2023-04-27 | 2026-03-23 |
| Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer Carboplatin, Cisplatin, Cytoreductive Surgery - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma | Early Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 35 | 2022-06-13 | 2026-08-17 |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery Oregovomab, Paclitaxel, Carboplatin - Carcinoma, Ovarian Epithelial, Ovarian Neoplasms | Phase 3 | Active not recruiting | CanariaBio Inc. | 615 | 2020-08-25 | 2026-04-01 |
| The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors Exercise Counseling, Aerobic Exercise, Physiological Support - Ovarian Cancer, Fallopian Tube Adenocarcinoma | Not applicable | Terminated | University of Washington | 64 | 2018-12-05 | 2023-11-29 |
| Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2017-05-05 | 2024-03-13 |
| Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 40 | 2016-09-01 | 2021-10-06 |
| Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer Biopsy Procedure, Biospecimen Collection, Cediranib Maleate - Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 70 | 2016-05-23 | 2026-09-29 |
| Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer Cediranib, Cediranib Maleate, Computed Tomography - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 582 | 2016-05-03 | 2026-10-01 |
| Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Laboratory Biomarker Analysis, BMN 673 - Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 4 | 2015-06-02 | 2022-02-24 |
| MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Bevacizumab, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 17 | 2015-03-13 | 2025-12-11 |
| MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 34 | 2014-04-25 | 2026-08-24 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers Bevacizumab, Laboratory Biomarker Analysis, Nab-paclitaxel - Cervical Adenocarcinoma, Cervical Adenosarcoma | Phase 1 | Completed | Mayo Clinic | 43 | 2014-02-24 | 2024-07-26 |
| Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Behavioral Dietary Intervention, Compliance Monitoring, Counseling - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Unknown | Gynecologic Oncology Group | 1070 | 2012-06-18 | 2018-02-19 |
| Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Chemotherapy, Propranolol Hydrochloride, Quality-of-Life Assessment - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 32 | 2012-03-09 | 2019-08-29 |
| Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Elesclomol Sodium, Paclitaxel - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Completed | GOG Foundation | 58 | 2010-12-13 | 2021-10-20 |
| First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Bevacizumab, Carboplatin, Paclitaxel - Fallopian Tube Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 33 | 2010-04-14 | 2022-10-28 |
| Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bortezomib, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 33 | 2010-04-05 | 2019-08-09 |
| Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bevacizumab, Carboplatin, Cisplatin - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1560 | 2009-08-11 | 2026-06-02 |
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Docetaxel - Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1052 | 2007-12-06 | 2025-12-30 |
| YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Terminated | Gynecologic Oncology Group | 2500 | 2007-09-01 | 2018-05-22 |
Showing 20 of 22. Sign in to see all of them.
Fallopian Tube Neoplasms (19) · Ovarian Neoplasms (16) · Brenner Tumor (12) · Adenocarcinoma, Clear Cell (1) · Adenocarcinoma, Mucinous (1) · Carcinoma (1) · Carcinoma, Ovarian Epithelial (1) · Peritoneal Neoplasms (1)
Adnexal Diseases (21) · Female Urogenital Diseases (21) · Female Urogenital Diseases and Pregnancy Complications (21) · Genital Diseases (21) · Genital Diseases, Female (21) · Genital Neoplasms, Female (21) · Neoplasms (21) · Urogenital Diseases (21) · Urogenital Neoplasms (21) · Neoplasms by Site (20) · Endocrine System Diseases (19) · Fallopian Tube Diseases (19) · Gonadal Disorders (19) · Ovarian Diseases (19) · Endocrine Gland Neoplasms (16)
Paclitaxel (11) · Taxes (11) · Bevacizumab (9) · Disulfides (9) · Immunoglobulin G (9) · Carboplatin (7) · Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Biopsy (2) · Cisplatin (2) · Doxorubicin (2) · Gemcitabine (2) · Platinum (2) · Topotecan (2)
National Cancer Institute (NCI) (6) · M.D. Anderson Cancer Center (4) · Mayo Clinic (3) · GOG Foundation (2) · Gynecologic Oncology Group (2) · Roswell Park Cancer Institute (2) · CanariaBio Inc. (1) · Ohio State University Comprehensive Cancer Center (1) · University of Washington (1)
United States (22) · South Korea (4) · Canada (3) · Japan (3) · Argentina (1) · Belgium (1) · Brazil (1) · Chile (1) · Czechia (1) · Hungary (1) · India (1) · Italy (1) · Mexico (1) · Puerto Rico (1) · Spain (1)
Emese Zsiros (2) · Anil K. Sood, MD (1) · Anil Sood (1) · Bradley J Monk (1) · David Alberts (1) · Don Dizon (1) · Evanthia Galanis, M.D. (1) · Evanthia Galanis, MD (1) · Floor Backes, MD (1) · Joan L Walker (1) · Joyce F Liu (1) · Jung-min Lee (1) · Katherine Bell-McGuinn (1) · Kathryn Pennington (1) · Larry J Copeland (1)
PMID 37185961, PMID 21941283, PMID 22204724, PMID 23219660, PMID 26487588, PMID 27394382, PMID 28341300, PMID 28438473, PMID 29550184, PMID 30309721, PMID 31002578, PMID 31216226, PMID 31722153, PMID 32379297, PMID 33211063, PMID 35144591, PMID 35759733, PMID 36252167, PMID 36608382, PMID 39361946, PMID 39638782
U10CA180868 (8), U10CA027469 (7), P30CA016672 (2), P50CA083639 (1), P50CA136393 (1), R01CA136547 (1), R01CA200507 (1), R01CA267690 (1), R21CA215662 (1), U10CA101165 (1), U10CA180830 (1), UG1CA189867 (1), UM1CA186644 (1), UM1CA186686 (1), UM1CA186690 (1)